Clinical Trials Logo

Clinical Trial Summary

Background:

- Neurocysticercosis (NCC) is caused by tapeworms that infect people. NCC can lead to serious brain problems such as seizures, sevre headaches and difficulties with movements or sensation in the limbs. Researchers want to learn more about the different ways in which people in the United States present with this disease and how they respond to standard and newer treatments.

Objective:

- To learn about the different forms of NCC that occurs throughout North America and how patients with these forms respond to treatment.

Eligibility:

- Adults age 18 or older with NCC.

Design:

- Participants will be screened with:

- Medical history and physical exam.

- A computed tomography (CT) brain scan The participant will lie still on a table that slides into a large donut-shaped scanner.

- Blood drawn through an arm vein for analysis

- A magnetic resonance imaging (MRI) scan of the brain and spine. They will lay flat in a long metal cylinder as the machine makes images of the body. During the scan, participants will receive a contrast agent through an IV that allows high resolution imaging of the brain and spine

- Participants will visit the clinic at 0, 1, 2, 3, 6, 12, and 24 months (7 times), and depending on the need for monitoring, more times. Participants will receive a schedule that will explain the procedures done at each visit.

- At these visits, participants may:

- Repeat the screening procedures.

- Be asked about their NCC symptoms and their physical and mental health.

- Have a urine test.

- Take a test of their ability to concentrate, their memory and spatial recognition.

- Have a lumbar puncture, if indicated by the state and severity of infection. A needle will be inserted through the skin and into the space between the bones in the back. Cerebrospinal fluid will be removed.


Clinical Trial Description

Neurocysticercosis (NCC) is the most common helminthic CNS infection and the main cause of adult-onset seizures in low-to-middle income countries. Studies have documented significant endemicity in Latin America, Eastern Europe, sub-Saharan Africa, India and other parts of the world. The prevalence of NCC in North America is rising as a result of increased migration of people with the disease and, occasionally, immigration of individuals with asymptomatic tapeworms. Despite the gains in knowledge and understanding of the epidemiology, pathophysiology, diagnosis, and treatment, clinical care continues to be hampered by unanswered fundamental questions related to optimal diagnosis, staging, treatment, and follow-up of patients with NCC.

This multi-center, natural history study seeks to characterize: the frequency of the various forms of NCC in North American populations; the spectrum of treatment and management strategies across the North American Cysticercosis Consortium; and the response to therapy by evaluating a number of endpoints related to disease evolution and treatment, such as burden of disease, cognitive changes, radiographic changes, and treatment complications. This study will inform future research studies needed to eventually establish standardized management protocols for each form of this complex infection.

Subjects will have visits at screening, baseline, 1, 2 (optional), 3, 6, 12, and 24 months. Evaluations will include assessment of clinical status, antigen assays, radiographic imaging, functional assessments, immunologic evaluations, cognitive assessments, and quality of life measures. Additional clinically indicated visits may be scheduled as needed. This study does not provide any interventional therapies but will collect data on the course of treatment. Diagnostic examinations, consultations and medical treatment will be determined by the study clinician. Any samples removed for medical indications related to NCC may be evaluated for research purposes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02233855
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase
Start date September 3, 2014
Completion date June 13, 2017

See also
  Status Clinical Trial Phase
Completed NCT00527579 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB Phase 1
Completed NCT00526916 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28 Phase 1
Completed NCT02234570 - Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole Phase 1
Terminated NCT02947581 - Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) Phase 3
Completed NCT02243644 - Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT Phase 3
Not yet recruiting NCT06376396 - Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis Phase 4
Completed NCT03874689 - Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
Completed NCT00441285 - Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) Phase 2/Phase 3
Not yet recruiting NCT04706819 - Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
Completed NCT00283699 - A Pilot Study of Neurocysticercosis Treatment Phase 3
Terminated NCT02945527 - Treatment of Peri-calcification Edema in Neurocysticercosis (NCC) Phase 2/Phase 3
Completed NCT00290823 - Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients Phase 3
Completed NCT03834337 - Treatment of Patients With Active Neurocysticercosis in Eastern Africa
Completed NCT03851419 - The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania